search
Back to results

A Safety,Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

Primary Purpose

Schizophrenia

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
JX11502MA
Placebo
Sponsored by
Zhejiang Jingxin Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male or female subjects;
  2. The age is between 18 and 45 years old (including the margin value);
  3. Male ≥50 kg, female ≥45 kg, the body mass index (BMI) of subjects ranged from 19 to 28 kg/m2 (including the boundary value);
  4. Be able to understand informed consent, voluntarily participate in clinical trials and sign informed consent;
  5. Be able to complete the experiment according to the research plan. Those who do not meet one of the above conditions shall not be selected as subjects.

Exclusion Criteria:

  1. The researcher judged that the subjects has current and past medical diseases or dysfunction history that may affect clinical trial, including but not limited to diseases of central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system and blood system;
  2. Suffering from mental illness or previous history of mental illness;
  3. Have a history of ophthalmic diseases, such as abnormal color vision, retinitis pigmentosa, macular degeneration, etc;
  4. Have a history of malignant tumors or other diseases that are not suitable for clinical trials;
  5. Any surgical situation or condition that may significantly affect the absorption, distribution, metabolism and excretion of drugs, or any surgical condition that may harm the subjects participating in this trial; Such as gastrointestinal surgery history (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcer, gastrointestinal bleeding history, etc.;
  6. Those who have allergic history of similar drug, allergic disease history or allergic constitution history;
  7. Those who are addicted to tobacco within one year before screening and smoke more than 10 cigarettes or the same amount of tobacco average every day;
  8. Those who are addicted to alcohol within one year before screening, and the average weekly alcohol intake exceeds 14 units (1 unit =285 mL beer or 25 mL spirits or 150 mL wine) or those who are positive for alcohol breath test;
  9. Those who have a history of drug and drug abuse within one year before screening, or those who are positive for urine drug screening;
  10. Physical examination, present medical history and vital signs, which are judged by researchers to be abnormal and have a clinical significance;
  11. Resting pulse rate < 55 beats/min or > 100 beats/min; Systolic pressure < 90 mmHg or > 140 mmHg, diastolic pressure < 60 mmHg or > 90 mmHg;
  12. Abnormal and has a clinical significance of 12-lead electrocardiogram (ECG) examination result judged by researchers; Or appears following ECG abnormalities: PR interval > 220 ms, QRS complex web time limit > 120 ms, long QT syndrome (QTC > 450 ms);
  13. Family history of sudden cardiac death (Lower than 40 years old);
  14. Abnormal and have clinical significance of blood routine examination and urine routine examination;
  15. Exceeded the normal limit of aspartate transferase (AST), alanine transferase (ALT), creatinine (Cr) and urea nitrogen (BUN) .
  16. Subjects with positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab) and syphilis seroreaction (TRUST);
  17. Pregnant and lactating women, or those who have the ability to conceive/pregnant, don't agree to adopt recognize effective methods of contraception during the study period and within 3 months after stopping treatment;
  18. Those who take any drugs within 2 weeks before before enrolling the trial, including prescription drugs and over-the-counter drugs;
  19. Blood donation or blood loss ≥200 mL within 3 months before enrolling, or history of using blood products;
  20. Participated any clinical trial within 3 months before enrolling the trial;
  21. Those who have a history of surgery within 3 months before enrollment, or haven't recover from surgery, or have expected surgical plan during the trial;
  22. Don't agree to comply with the following conditions during the trial: prohibit the use of alcohol, tobacco or caffeinated beverages and avoid strenuous exercise;
  23. Person those are directly related to this trial;
  24. Researcher decide, subjects those are non-suitable to participate in this trial.

Sites / Locations

  • Shanghai Mental Health CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg

Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg

Arm Description

Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.

Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..

Outcomes

Primary Outcome Measures

The incidence rate of adverse reactions
Count the number of subjects with adverse reactions during the trial and calculate the incidence of adverse reactions(Number of subjects with adverse reactions / total number of subjects* 100%).The adverse reactions include drowsiness、weakness hiccup、vomit、anorexia、nausea、insomnia、dry mouth、dizzy and stomach distention

Secondary Outcome Measures

Cmax
Maximum Serum Concentration of the parent drug
Tmax
Time to Reach the Maximum Serum Concentration of the parent drug
AUC
Area Under the Serum Concentration-Time Curve of the parent drug
t1/2
Elimination half-life period

Full Information

First Posted
December 12, 2021
Last Updated
January 31, 2022
Sponsor
Zhejiang Jingxin Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05233657
Brief Title
A Safety,Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule
Official Title
An Evaluation of Safety, Tolerability and Pharmacokinetics of Single Oral Dose of JX11502MA Capsule on Healthy Human: A Phase Ia, Single Center, Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 4, 2020 (Actual)
Primary Completion Date
January 31, 2022 (Anticipated)
Study Completion Date
February 28, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zhejiang Jingxin Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetic characteristics of JX11502MA capsule on healthy human, and to explore the relationship between the dose, pharmacokinetic parameters and safety of JX11502MA capsule,so as to provide basis for the follow-up clinical trials (multi-dose tolerability, pharmacokinetics and phase II trial, etc.).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg
Arm Type
Experimental
Arm Description
Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.
Arm Title
Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg
Arm Type
Placebo Comparator
Arm Description
Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..
Intervention Type
Drug
Intervention Name(s)
JX11502MA
Intervention Description
Oral capsule
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral capsule
Primary Outcome Measure Information:
Title
The incidence rate of adverse reactions
Description
Count the number of subjects with adverse reactions during the trial and calculate the incidence of adverse reactions(Number of subjects with adverse reactions / total number of subjects* 100%).The adverse reactions include drowsiness、weakness hiccup、vomit、anorexia、nausea、insomnia、dry mouth、dizzy and stomach distention
Time Frame
Day(1)-Day(7)
Secondary Outcome Measure Information:
Title
Cmax
Description
Maximum Serum Concentration of the parent drug
Time Frame
Day(1)-Day(7)
Title
Tmax
Description
Time to Reach the Maximum Serum Concentration of the parent drug
Time Frame
Day(1)-Day(7)
Title
AUC
Description
Area Under the Serum Concentration-Time Curve of the parent drug
Time Frame
Day(1)-Day(7)
Title
t1/2
Description
Elimination half-life period
Time Frame
Day(1)-Day(7)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or female subjects; The age is between 18 and 45 years old (including the margin value); Male ≥50 kg, female ≥45 kg, the body mass index (BMI) of subjects ranged from 19 to 28 kg/m2 (including the boundary value); Be able to understand informed consent, voluntarily participate in clinical trials and sign informed consent; Be able to complete the experiment according to the research plan. Those who do not meet one of the above conditions shall not be selected as subjects. Exclusion Criteria: The researcher judged that the subjects has current and past medical diseases or dysfunction history that may affect clinical trial, including but not limited to diseases of central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system and blood system; Suffering from mental illness or previous history of mental illness; Have a history of ophthalmic diseases, such as abnormal color vision, retinitis pigmentosa, macular degeneration, etc; Have a history of malignant tumors or other diseases that are not suitable for clinical trials; Any surgical situation or condition that may significantly affect the absorption, distribution, metabolism and excretion of drugs, or any surgical condition that may harm the subjects participating in this trial; Such as gastrointestinal surgery history (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcer, gastrointestinal bleeding history, etc.; Those who have allergic history of similar drug, allergic disease history or allergic constitution history; Those who are addicted to tobacco within one year before screening and smoke more than 10 cigarettes or the same amount of tobacco average every day; Those who are addicted to alcohol within one year before screening, and the average weekly alcohol intake exceeds 14 units (1 unit =285 mL beer or 25 mL spirits or 150 mL wine) or those who are positive for alcohol breath test; Those who have a history of drug and drug abuse within one year before screening, or those who are positive for urine drug screening; Physical examination, present medical history and vital signs, which are judged by researchers to be abnormal and have a clinical significance; Resting pulse rate < 55 beats/min or > 100 beats/min; Systolic pressure < 90 mmHg or > 140 mmHg, diastolic pressure < 60 mmHg or > 90 mmHg; Abnormal and has a clinical significance of 12-lead electrocardiogram (ECG) examination result judged by researchers; Or appears following ECG abnormalities: PR interval > 220 ms, QRS complex web time limit > 120 ms, long QT syndrome (QTC > 450 ms); Family history of sudden cardiac death (Lower than 40 years old); Abnormal and have clinical significance of blood routine examination and urine routine examination; Exceeded the normal limit of aspartate transferase (AST), alanine transferase (ALT), creatinine (Cr) and urea nitrogen (BUN) . Subjects with positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab) and syphilis seroreaction (TRUST); Pregnant and lactating women, or those who have the ability to conceive/pregnant, don't agree to adopt recognize effective methods of contraception during the study period and within 3 months after stopping treatment; Those who take any drugs within 2 weeks before before enrolling the trial, including prescription drugs and over-the-counter drugs; Blood donation or blood loss ≥200 mL within 3 months before enrolling, or history of using blood products; Participated any clinical trial within 3 months before enrolling the trial; Those who have a history of surgery within 3 months before enrollment, or haven't recover from surgery, or have expected surgical plan during the trial; Don't agree to comply with the following conditions during the trial: prohibit the use of alcohol, tobacco or caffeinated beverages and avoid strenuous exercise; Person those are directly related to this trial; Researcher decide, subjects those are non-suitable to participate in this trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huafang Li, Doctor
Phone
(86)021-34773128
Email
lhlh_5@163.com
Facility Information:
Facility Name
Shanghai Mental Health Center
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huafang Li, Doctor
Phone
(86)021-34773128

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Safety,Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

We'll reach out to this number within 24 hrs